FPIN's clinical inquiries. Medical treatment of benign prostatic hyperplasia.
Rich
Kevin T
KT
Family Medicine Residency of Idaho, Boise, Idaho, USA. kevin.rich@fmridaho.org
Safranek
Sarah
S
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D018120:Finasteride / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008517:Phytotherapy / Q000379:methods*; D017410:Practice Guidelines as Topic; D011224:Prazosin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013449:Sulfonamides / Q000627:therapeutic use; D000077409:Tamsulosin; D016896:Treatment Outcome
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D013449:Sulfonamides; D018120:Finasteride; C041226:Terazosin; D000077409:Tamsulosin; D011224:Prazosin